ABIRISK
What it found
No result yet.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
- Interferon beta-1b
Interferon alpha/beta receptor agonist
What it measured
Main measures
To identify early biomarkers within 3 months of IFN-beta treatment able to predict immunization against IFN-beta within the 18 months of treatment in MS patients
Blood or spinal fluid markers
Other measures (1)
• To characterize kinetic development of binding antibodies against IFNbeta for the prediction of neutralizing antibodies
Immune response
Who could take part
MS (type not specified)
Inclusion: - Male and female patients of more than 18 years old diagnosed with MS according to the valid McDonald criteria at the time of diagnosis Exclusion: - Patients who had previous treatment with any IFNbeta preparation or neutralizing antibodies against IFNbeta at baseline visit
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To identify early biomarkers within 3 months of IFN-beta treatment able to predict immunization against IFN-beta within the 18 months of treatment in MS patients
Papers
Loading reviews and guidelines…
Related trials
- INFORM
Running, not recruiting
Still running
- Drug Repurposing Using Metformin for Improving the Therap…
Phase 2 · Status unknown
Missed its main goal
- US PROmyBETAapp2.0: A Study to Learn More About the Medic…
Completed
No result found
- PROmyBETAappGame: a Study to Learn More About the Medicat…
Completed
No result found
- EPID Multiple Sclerosis Pregnancy Study
Completed
No result found
- Comparison Study of PF530 and Betaferon in Healthy Subjects
Phase 1 · Completed
No result found
History
Started
Nov 2013
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error